HPV antigens in squamous intraepithelial lesions: Immunohistochemistry with Pl6ink4a, VIROACTIV® and Ki67

Antígenos de VPH en lesiones intraepiteliales escamosas: Inmunohistoquímica con Pl6ink4a, VIROACTIV® y Ki67

The most widely used method for the early detection of cancer of the uterine cervix (CCU) is cervicovaginal cytology (CCV), which has amply demonstrated its usefulness given its ability to detect precursor lesions of the CCU. which has contributed to significantly reduce morbidity and mortality due to this neoplasm. The immediate consequence of the sampling programs has been the significant increase in the number of cervical biopsies. His histological analysis is important because it is considered the reference standard (gold standard) on which the clinician bases himself to plan the appropriate treatment for these patients. However, there are cases in which the precise histopathological diagnosis is subjective and susceptible to varied opinions among the observers, a fact that has prompted the search for alternative techniques such as immunohistochemistry, to help establish a more reliable prognostic value in preneoplastic lesions of the Cervix This is why our study has as main objective to determine the IHC expression of HPV antigens (subtype of high risk) and the cell proliferation index in low-grade squamous intraepithelial lesions (LIEBG) and high-grade squamous intraepithelial lesions (LIEAG). , using the biomolecular markers Ki67, Pl6ink4a and Viroactiv®. Abbreviations: HPV, human papillomavirus; CCU, carcinoma of the uterine cervix; CCV, cervicovaginal cytology; LIE, squamous intraepithelial lesion; LIEBG, low-grade squamous intraepithelial lesion; LIEAG, high-grade squamous intraepithelial lesion; NIC, intraepithelial neoplasia; CIS, carcinoma in situ; IHC, immunohistochemistry.

1. Reeves WC, Brinton LA, García M, Brenes MM, Herrero R, Gaitán E, Tenorio F, de Britton RC, Rawls WE. Human papillomavirus infection and cervical cancer in Latin America. N Engl J Med. 1989 Jun 1;320(22):1437-41.

2. Hernández-Avila M, Lazcano-Ponce EC, de Ruíz PA, Romieu I. Evaluation of the cervical cancer screening programme in Mexico: a population-based case-control study. Int J Epidemiol. 1998 Jun;27(3):370-6.

3. Gonzalez M. Manual de normas técnico-administrativas para el programa de detención y control del cáncer de cuello uterino. 2' ed. Bogotá : Secretaria de Salud; 2005.

4. Solomon D, Nayar R, editors. The Bethesda system for reporting cervical cytology. 2nd. ed. New York: Springer; 2004.

5. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, Kurman RJ, Schmidt D, Stoler M, von Knebel Doeberitz M. p 1 6INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol. 2002 Nov;26(11):1389-99.

6. Robertson AJ, Anderson JM, Beck JS, Burnett RA, Howatson SR, Lee FD, Lessells AM, McLaren KM, Moss SM, Simpson JG, et al. Observer variability in histopathological reporting of cervical biopsy specimens. J Clin Pathol. 1989 Mar;42(3):231-8.

7. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003 Dec 6;362(9399):1871-6.

8. Mitchell MF, Hittelman WK, Lotan R, Nishioka K, Tortolero-Luna G, Richards-Kortum R, Wharton JT, Hong WK. Chemoprevention trials and surrogate end point biomarkers in the cervix. Cancer. 1995 Nov 15;76(10 Suppl):1956-77.

9. López G. HPV: Estudio morfológico e inmunohistoquímico en biopsias del cuello uterino. Rey Ecuat Gin Obst. 1993 Abr;2(2):31-45.

10. Firzlaff JM, Kiviat NB, Beckmann AM, Jenison SA, Galloway DA. Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology. 1988 Jun;164(2):467-77.

11. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology. 1990 Dec;17(6):489- 503.

12. Queiroz C, Silva TC, Alves VA, Villa LL, Costa MC, Travassos AG, Filho JB, Studart E, Cheto T, de Freitas LA. Pl6INK4a expression as a potential prognostic marker in cervical pre-neoplastic and neoplastic lesions. Pathol Res Pract. 2006 Feb;202(2):77-83.

13. Mittal KR, Demopoulos RI, Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am J Surg Pathol. 1993 Feb;17(2):117-22.

14. Raju GC. Expression of the proliferating cell nuclear antigen in cervical neoplasia. Int J Gynecol Pathol. 1994 Oct;13(4):337-41.

15. Trunk MJ, Dallenbach-Hellweg G, Ridder R, Petry KU, Ikenberg H, Schneider V, von Knebel Doeberitz M. Morphologic characteristics of p 1 6INK4a-positive cells in cervical cytology samples. Acta Cytol. 2004 Nov- Dec;48(6):771-82.

16. Toro M, Llombart-Bosch A. Detección inmunohistoquímica de la proteína Ll de Virus Papiloma Humano (HPV) de alto riesgo en citologías y biopsias de cuello uterino. Rev Esp Patol. 2005 Ene;38(1):8-13.

17. Al-Saleh W, Delvenne P, Greimers R, Fridman V, Doyen J, Boniver J. Assessment of Ki-67 antigen immunostaining in squamous intraepithelial lesions of the uterine cervix. Correlation with the histologic grade and human papillomavirus type. Am J Clin Pathol. 1995 Aug;104(2):154-60.